Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol

详细信息	查看全文 | 推荐本文 |

• 作者：Elizabeth Alli^a ; ^{ealli@stanford.edu} ; James M. Ford^a ; ^b ; ^{jmf@stanford.edu}
• 关键词：BRCA1 ; Breast Cancer Susceptibility Gene 1 ; ER- 伪 ; estrogen receptor-伪 ; PR ; progesterone receptor ; BER ; base-excision repair ; ROS ; reactive oxygen species ; S.D. ; standard deviation ; MTT ; 1-(4 ; 5-dimethylthiazol-2-yl)-3 ; 5-diphenylformazan ; hOGG1 ; human 8-
• 刊名：DNA Repair
• 出版年：2012
• 期刊代码：121_15687864
• 类别：ch
• 出版时间：1 May, 2012
• 卷：11
• 期：5
• 页码：522-524
• 文件大小：481 K

摘要

The basal-like subtype of breast cancers, including those that contain germline mutations in BRCA1, tend to be triple-negative (i.e. lack expression of estrogen and progesterone receptors and lack overexpression/amplification of the HER2/neu oncogene), which renders them relatively insensitive to existing 鈥渢argeted鈥?therapy. BRCA1-mutated and basal-like breast cancers harbor compromised ability for repairing oxidative DNA damage by the DNA base-excision repair pathway. We found that this defective repair mechanism predicts sensitivity to elesclomol, an experimental therapeutic that produces elevated levels of oxidative DNA damage. In conclusion, BRCA1-mutated and/or basal-like breast cancers may benefit from treatment regimens that include elesclomol.